Clinicians can identify patients at high risk of developing aggressive multiple sclerosis (MS) based on early clinical markers within the first 12 months following symptom onset.
Why this matters
There is currently an unmet need for early identification of patients at high risk of developing aggressive MS who would benefit from proactive treatment.
This is the largest study that investigated identification of early clinical markers of aggressive MS and its results can be directly translated for clinical application.
International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.
No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.